Hepatitis B Virus (HBV) Perinatal Exposure Follow-up by CIA, Panel
Also known as: HBV PAN PN
Use
Intended for infants born to hepatitis B (HBV) infected women to assess the infant’s immune response to the initial vaccination and detect any early onset of HBV infection. This panel helps evaluate if the child has acquired immunity post-vaccination or remains susceptible to HBV due to insufficient antibody response. Early detection of HBV is critical in devising a treatment plan to mitigate any long-term health issues associated with HBV infection.
Special Instructions
This test is New York state approved. The panel should not be used for purposes such as blood donor screening, associated reentry protocols, or screening of human cells, tissues, and cellular- and tissue-based products (HCT/P).
Limitations
The assays within this panel are optimized for clinical diagnostics post-vaccination and are not designed for screening applications related to blood donation or transplantation products. False positives can occur, and if clinical evidence doesn't support the result, further testing on a new specimen is recommended to clarify the diagnosis.
FDA ApprovedNew York Approved
Methodology
Immunoassay (CLIA)
Biomarkers
LOINC Codes
- 48767-8
- 5193-8
- 5196-1
- 5196-1
- 5193-8
- 48767-8
Result Turnaround Time
1 day
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
3 mL
Minimum Volume
1.5 mL
Container
Serum separator tube (SST)
Collection Instructions
Separate from cells ASAP or within 2 hours of collection. Transfer to an ARUP standard transport tube.
Storage Instructions
Refrigerated storage is necessary.
Causes for Rejection
Heparinized plasma, particulate material, heat-inactivated, severely hemolyzed, or lipemic specimens.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | Unacceptable |
| Refrigerated | 1 week |
| Frozen | Indefinitely (avoid repeated freeze/thaw cycles) |